Casdin entities add LAB shares, reporting over 64M indirectly held
Rhea-AI Filing Summary
Standard BioTools Inc. (LAB) large shareholder and director-affiliated entities managed by Eli Casdin reported open-market purchases of common stock. On 11/18/2025, they bought 275,000 shares at a weighted average price of $1.2342, followed by 350,000 shares at $1.2826 on 11/19/2025 and 450,000 shares at $1.3028 on 11/20/2025.
After these transactions, one indirect holding line shows 64,050,000 shares of LAB common stock, with other lines reporting 2,901,062 shares directly and additional indirect positions of 13,939,637 and 2,744,219 shares. The filing explains that various Casdin funds hold these positions and that Eli Casdin and related entities may be deemed to beneficially own the securities through their advisory and general partner roles, while each reports ownership only to the extent of its economic interest.
Positive
- None.
Negative
- None.
Insights
Large insider purchases by an existing 10% owner/director increase indirect holdings and signal stronger economic exposure to the issuer.
This Form 4 reports open-market purchases of **STANDARD BIOTOOLS INC.** common stock by entities affiliated with **Eli Casdin** over three days, as a group already identified as a director and 10% owner. The Casdin Partners Master Fund bought **275,000**, **350,000**, and **450,000** shares on
The filing explains that each daily price is an average of multiple trades within narrow ranges, with a commitment to provide detailed breakdowns on request. Ownership is spread across several vehicles (Master Fund, Growth Equity Fund and Fund II, related GPs, and **Casdin Capital, LLC**), all of which may be deemed to share beneficial ownership, while each party disclaims ownership beyond its economic interest. No derivative securities are reported in Table II, so the changes here reflect straightforward cash equity accumulation rather than option or warrant activity.
Eli Casdin is described as deputized to represent these entities on the issuer’s board, so these purchases link board-level representation with larger economic stakes. Key items to watch over the coming months are any follow-on Form 4 filings that change these share counts, and any future disclosures that clarify how this concentrated, board-connected ownership interacts with governance or corporate actions. The most concrete near-term reference point is the cluster of purchases completed by
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock, $0.001 par value per share | 450,000 | $1.3028 | $586K |
| Purchase | Common Stock, $0.001 par value per share | 350,000 | $1.2826 | $449K |
| Purchase | Common Stock, $0.001 par value per share | 275,000 | $1.2342 | $339K |
| holding | Common Stock, $0.001 par value per share | -- | -- | -- |
| holding | Common Stock, $0.001 par value per share | -- | -- | -- |
| holding | Common Stock, $0.001 par value per share | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2247 to $1.2421. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2758 to $1.2870. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2788 to $1.3500 . The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. The securities are owned directly by Eli Casdin. The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
